Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
145M
-
Number of holders
-
219
-
Total 13F shares, excl. options
-
133M
-
Shares change
-
+4.98M
-
Total reported value, excl. options
-
$1.81B
-
Value change
-
+$50.4M
-
Put/Call ratio
-
0.39
-
Number of buys
-
105
-
Number of sells
-
-114
-
Price
-
$13.60
Significant Holders of Denali Therapeutics Inc. - Common Stock (DNLI) as of Q1 2025
259 filings reported holding DNLI - Denali Therapeutics Inc. - Common Stock as of Q1 2025.
Denali Therapeutics Inc. - Common Stock (DNLI) has 219 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 133M shares
of 145M outstanding shares and own 91.48% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (13.8M shares), BAILLIE GIFFORD & CO (12.1M shares), VANGUARD GROUP INC (11.8M shares), WELLINGTON MANAGEMENT GROUP LLP (11.4M shares), FMR LLC (7.41M shares), UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC (6.77M shares), Temasek Holdings (Private) Ltd (5.36M shares), Capital Research Global Investors (4.77M shares), STATE STREET CORP (4.46M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (4.37M shares).
This table shows the top 219 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.